Innovation at the core
Fortimedix Surgical is committed to driving the evolution of minimally invasive surgery through smart innovation across surgical specialties. As a technology-driven company dedicated to improving the quality of life of patients throughout the world we identify and address unmet needs in human healthcare, a strategy that is well-integrated into our research and development approach.
The symphonX™ Surgical Platform is our first commercial platform for minimally invasive surgery, and is FDA cleared for use in abdominal laparoscopic surgery. Beyond the initial focus on general surgery, the recently launched shorter version of the symphonX™ Instruments portfolio has been used during several gynecologic procedures including tubal sterilization and ovarian cyst treatment with positive results, confirming the versatility of the platform across surgical specialties.
Under the leadership and guidance of Dr. Karl-Hermann Fuchs, one of our Scientific Advisory Board members, we are developing a surgical solution for less invasive transanal colon resection (TaCR). Together with his son, Dr. Hans F. Fuchs, several cadaver and dry lab studies were performed with a modified version of the symphonX™ Surgical Platform. These results were presented as part of the Emerging Technology Session of the SAGES 2016 Annual Meeting in Boston (March 2016) and the Amazing Technology Session of the 25th International Congress of the European Association for Endoscopic Surgery (EAES) in Frankfurt am Main (June 2017) by Dr. Hans F. Fuchs, and during the American Society For Gastrointestinal Endoscopy (ASGE) NOSCAR Summit in Downers Grove (July 2017) by Dr. Karl-Hermann Fuchs.
Certain statements herein include “forward-looking” statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words.
All forward looking statements involve risks and uncertainties, including, but not limited to, the protection of intellectual property, changes to governmental regulation of medical devices, the introduction of new products into the marketplace by competitors, changes to the competitive environment, the acceptance of new products in the marketplace, conditions of the surgical industry and economic and political conditions globally.
Actual results may differ materially from those contemplated or implied by the forward-looking statements. The forward-looking statements speak only as of the date of this release and Fortimedix Surgical assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.